Pfizer's $10B Innovent bet meets the China-data reckoning
A $10B Pfizer-Innovent pact, a House bill to sweep biotech into COINS, and two China-only ASCO plenaries land in one week — and the bridging-study question is suddenly on the critical path.
Regulatory & Conduct
FDA opens the door to platform borrowing in genome editing
CBER's draft guidance on "prior knowledge" lands the same week three in vivo cell and gene readouts make the question of borrowing unavoidable. Comments close September 1.
Who Designs the Trial Is Now a Regulatory Variable
Two new audits — 15 years of LMIC authorship, and SARS-CoV-2 vaccine eligibility criteria — turn diversity rhetoric into an estimand problem sponsors will be asked about.
The open-data literature now has a measured contamination rate
Spick et al. put a number on the paper-mill exploitation of FAERS, NHANES, UK Biobank and the rest — 11,577 excess publications in 2025 — just as EMA's concept paper on external controls lands.
Tavneos Withdrawal Exposes What BIMO Can't See
CDER's proposed withdrawal of avacopan rests on post-unblinding readjudication that no inspection caught — and lands in the same week as new BIMO guidance, ISO 14155:2026, and a peer-reviewed audit of QTL methods.
Three Guidance Events in One Week Redraw the Statistical Rulebook
FDA's 25-year-overdue BE statistics overhaul, ICH M11's US adoption, and the MHRA's IMA proposal landed simultaneously — at a moment when none of the institutions delivering them can promise smooth implementation.
ICH M11 Is Final — but the Agency That Makes It Matter Is Unsteady
CeSHarP finalization sets a decade-defining protocol standard — just as FDA generates the kind of unpredictability that makes any pre-submission agreement harder to trust.